Blood

1. MARCAIS A
   Targeting PD-L1 to treat ATLL?
   Blood. 2024;143:1320-1322.
   

   >> Share

   
   
2. LOCKE FL, Oluwole OO, Kuruvilla J, Thieblemont C, et al
   Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
   Blood. 2024 Apr 1:blood.2023021620. doi: 10.1182/blood.2023021620.
   

   >> Share

   
   

   
   BMC Cancer

3. ZHONG Y, Tan GW, Bult J, Veltmaat N, et al
   Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
   BMC Cancer. 2024;24:407.
   

   >> Share

   
   

   
   Br J Cancer

4. ABRAHAO R, Brunson A, Ruddy KJ, Li Q, et al
   Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study.
   Br J Cancer. 2024;130:1166-1175.
   

   >> Share

   
   

   
   Br J Dermatol

5. ROCCUZZO G, Calvao J, Dobos G, Morsia E, et al
   Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project.
   Br J Dermatol. 2024 Apr 5:ljae145. doi: 10.1093.
   

   >> Share

   
   

   
   Br J Haematol

6. ATALLAH-YUNES SA, Habermann TM, Khurana A
   Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
   Br J Haematol. 2024 Apr 5. doi: 10.1111/bjh.19425.
   

   >> Share

   
   
7. MILROD CJ, Kim KW, Raker C, Ollila TA, et al
   Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
   Br J Haematol. 2024 Apr 4. doi: 10.1111/bjh.19449.
   

   >> Share

   
   

   
   Cancer

8. GIRI S, Harmon C, Landier W, Chen Y, et al
   Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphoma.
   Cancer. 2024 Apr 5. doi: 10.1002/cncr.35298.
   

   >> Share

   
   

   
   Discov Oncol

9. LIU Y, Li Y, Zhang C, Yang X, et al
   Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma.
   Discov Oncol. 2024;15:105.
   

   >> Share

   
   

   
   Haematologica

10. BOURLON C, Roddie C, Menne T, Norman J, et al
    Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
    Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285010.
    

    >> Share

    
    
11. IKEDA D, Oura M, Uehara A, Tabata R, et al
    Prognostic relevance of tumor-infiltrating CD4(+) cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma.
    Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285038.
    

    >> Share

    
    

    
    Leuk Lymphoma

12. CUI C, Feng C, Rosenthal N, Wade SW, et al
    Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United States.
    Leuk Lymphoma. 2024 Apr 3:1-10. doi: 10.1080/10428194.2024.2331084.
    

    >> Share

    
    
13. SONG Y, Li J, Zhou K, Ke X, et al
    Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2024 Apr 1:1-6. doi: 10.1080/10428194.2024.2310141.
    

    >> Share

    
    

    
    Leukemia

14. REISS DJ, Nakayama Y, Weng AP, Stokes ME, et al
    High-plex imaging and cellular neighborhood spatial analysis reveals multiple immune escape and suppression patterns in diffuse large B-cell lymphoma.
    Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02239.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share